Clarivate identifies seven innovators in antibody drug conjugates in new companies to watch report

Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report london , june 19, 2024 /prnewswire/ -- clarivate plc (nyse:clvt), a leading global provider of transformative intelligence, has released its annual companies to watch report, highlighting seven innovative companies revolutionizing drug discovery and development. these companies are advancing antibody-drug conjugates (adcs) to deliver highly targeted cancer treatments with minimal side effects.
CLVT Ratings Summary
CLVT Quant Ranking